SlideShare a Scribd company logo
Towards Immune Modulation
against Vulnerable Plaque
Göran K Hansson
Center for Molecular Medicine
Karolinska Institutet
Stockholm, Sweden
Vulnerable Plaque Symposium
Chicago, IL, November 2002
Hansson, Libby, Schönbeck & Yan, Circ Res 2002
Potential targets for
immunomodulation of
atherosclerosis
• Specific antigens
– oxLDL, HSP65, β2GpI,
microbial
• C pneum, CMV, others
• Co-stimulatory
molecules
– CD40/CD40L, CD28/B7
• Cytokines
– IFNγ, TNFα (aggravating)
– IL-10, TGFβ (protective)
• Vaccines
• Recombinant proteins
• Antibodies
• Cells
• Small molecule drugs
Atherosclerosis in the absence of
adaptive immunity?
(G K Hansson & J Nilsson, in: Crawford & DiMarco, Cardiology)
CD4+
T cells aggravate atherosclerosis
in immunodeficient apoExSCID mice
*
ApoE-
SCID
ApoE-
T and B cells No CD4+
T Yes
transfer
Aortic lesion
size
Zhou, Nicoletti,
Elhage & Hansson
Circ 102:2919
2000
ApoE-
SCID
Immunosuppression to reduce
CD4+ T cell activity?
• General immunosuppression is likely to
reduce atherosclerosis
– Some support from animal studies
• But substantial side effects
– Infections
– Direct vascular effects of drugs
• Therefore, general immunosuppression is
unlikely to be used to treat atherosclerosis or
even vulnerable plaque
Complexity of immune
regulatory networks
• Counterbalancing cell subsets
• Idiotypic antibody networks
• Regulatory cytokines
The Th1/Th2 Paradigm
Th
IL-12
MHC
Peptide
TCRTCR
IFN-γ
IL-18
Th1
IFN-γ
MΦ
IFN-γ
B
Ab
DTH
InflammationAPC
APC Th
IL-4
Th2Th2
B
IL-3, 5
IL-4
IL-10
IL-13
-
IL-4, 10, 13
Antibodies
Allergy
Hypothesis: Th1/Th2 balance
controls atherosclerosis
– Th1 cells dominate in lesions and are
proatherogenic
• CD4+ Th1 cells (Hansson 89; Uyemura 96; Frostegård 99)
• Interferon-γ, TNF-α; IL-12, IL-18 (Zhou 00; Mallat 01;
Daugherty 01)
–Th2 cytokines that inhibit Th1 may be
antiatherogenic?
– IL-10-/-
B6 mice develop larger fatty streaks
– IL-10 administration reduces disease
» Mallat et al; Pinderski et al. 99
Increased atherosclerosis in
IL-10 deficient apoE-/-
mice
IL10-/-
E-/-
IL10+/+
E-/-
Caligiuri, Hansson, Rudling, Michel, Nicoletti 2002
*
100
50
Lesion size
(x 103 µm2)
in 16 wks
old mice
Antiatherosclerotic cytokines
- useful for therapy?
• Powerful, direct approach
• Recombinant cytokines available
• But these cytokines are usually
immunosuppressive / antiinflammatory,
therefore
– Increased sensitivity to infections
– Cytokine-specific side effects
• E.g. TGFβ – fibrosis
• Therefore, these cytokines might be useful in
acute coronary syndromes,
• although not in chronic atherosclerosis
Inflammation
Repair
Innate immunity / TLRs
Adaptive Th1 immunity
IFN-γ TNF-α, IL-1
Inhibitory cytokines
Cells?
IL-10
TGF-β
Ab?
Accelerated athero
Plaque activation
Reduced athero
Stable plaque
Silent disease
Immune regulation of plaque activity
B cells of atherosclerotic mice
carry atheroprotective immunity
0
50
100
150
200
250
Sham Sx Sx Sx
Transfer - - T B
*
*
‡
‡
Lesionsize
Caligiuri et al, JCI 109:745, 2002
ApoE mice
Sx, trf 6 wk age
Analysis 18 wk
Atheroprotective immunity
• Carried by spleen B cells
• Reduces lesion size and stage
• Reduces CD4+ T cell infiltration in
lesions
• Correlates with anti-oxLDL antibodies
• Protective effect of antibodies?
– Clearance of oxLDL?
Protective immunity against
atherosclerosis
• Can we induce it by immunization?
• A vaccination strategy
against atherosclerosis?
Protective immunization
1. Oxidized LDL
Parenteral immunization (sc)
Model: Mutant rabbits, mice
Antigen: OxLDL, MDA-LDL
Freund´s adjuvant
Repeated inj 3 wk intervals
Significant protection after 3 months!
Palinski PNAS 95; Ameli ATVB 96;
George Athero 99; Zhou ATVB 00
MDA-LDL ”vaccination”
reduces atherosclerosis
Immunogen (PBS) Plaque MDA-LDL
extract
ApoE-/-
mice
Immun wk 6 / FCA
Boost wk 8,10,12,14
Analysis wk 18
Zhou et al, ATVB 2000
Protective immunization
2. Heat shock protein 65/60
• HSP60 released upon cell injury and in
atherosclerosis
– Wick, Xu et al. 1992
• HSP65/60 X-reacts man-microbe
• Mucosal administration of HSP65
– Nasal, oral
• Reduced lesions in LDLR mice
– Maron, Libby, Weiner, Circ 2002
– Harats, Shoenfeld, George, JACC 2002
Inflammation
Repair
Innate immunity / TLRs
Adaptive Th1 immunity
IFN-γ TNF-α, IL-1
Inhibitory cytokines
Protective B cells
IL-10
TGF-β
Ab?
MΦ activation
Endothelial activation
Radicals
Proteinases
Prothrombotic state
Antiinflammation
Fibrosis
SMC proliferation
Antibody clearance
Immune regulation of plaque activity
Vaccine
Small molecule drugs that
modulate athero-immunity
• Pentoxifyllin
– Inhibits Th1 immune responses
– Inhibits atherosclerosis in mice
• Laurat et al Circ 2001
• Statins
– Inhibit Th1 responses!
• Kwak Nat Med 2000; Youssef Nature 2002
– Inhibit atherosclerosis in mice and men
Statins inhibit Th1 immunity
• Downregulate interferon-γ induced
HLA-II transcription in macrophages
– Kwak, Mach et al, Nature Med 2000
• Inhibit Th1 signalling
• Increase Th2 cytokines
• Inhibit autoimmune encephalomyelitis
– Youssef, Steinman et al, Nature 2002
Inflammation
Repair
Innate immunity / TLRs
Adaptive Th1 immunity
IFN-γ TNF-α, IL-1
Inhibitory cytokines
Protective B cells
IL-10
TGF-β
Ab
MΦ activation
Endothelial activation
Radicals
Proteinases
Prothrombotic state
Antiinflammation
Fibrosis
SMC proliferation
Antibody clearance
Immune modulation of vulnerable plaque
Vaccines
Drugs

More Related Content

What's hot

Esv2n15
Esv2n15Esv2n15
243 b cell
243 b cell243 b cell
Autoimmune disease
Autoimmune diseaseAutoimmune disease
Atherosclerosis an autoimmune disease
Atherosclerosis an autoimmune diseaseAtherosclerosis an autoimmune disease
Atherosclerosis an autoimmune disease
Society for Heart Attack Prevention and Eradication
 
Atherosclerosis, an autoimmune disease 2
Atherosclerosis, an autoimmune disease 2Atherosclerosis, an autoimmune disease 2
Atherosclerosis, an autoimmune disease 2
Society for Heart Attack Prevention and Eradication
 
kayleighreport2014
kayleighreport2014kayleighreport2014
kayleighreport2014
Kayleigh Cook
 
Aeha multipeptide and passive
Aeha multipeptide and passiveAeha multipeptide and passive
Atherosclerosis an autoimmune disease
Atherosclerosis  an autoimmune diseaseAtherosclerosis  an autoimmune disease
Atherosclerosis an autoimmune disease
Society for Heart Attack Prevention and Eradication
 
501 autoimmune disease
501 autoimmune disease501 autoimmune disease
06 rencontres biomédicale LIR A Tedgui
06 rencontres biomédicale LIR A Tedgui06 rencontres biomédicale LIR A Tedgui
06 rencontres biomédicale LIR A Tedgui
Association LIR
 
074 influenza infection effects
074 influenza infection effects074 influenza infection effects
Immunità acquisita nelle IBD
Immunità acquisita nelle IBDImmunità acquisita nelle IBD
Immunità acquisita nelle IBD
Gianfranco Tammaro
 
Drnaghavi
DrnaghaviDrnaghavi

What's hot (13)

Esv2n15
Esv2n15Esv2n15
Esv2n15
 
243 b cell
243 b cell243 b cell
243 b cell
 
Autoimmune disease
Autoimmune diseaseAutoimmune disease
Autoimmune disease
 
Atherosclerosis an autoimmune disease
Atherosclerosis an autoimmune diseaseAtherosclerosis an autoimmune disease
Atherosclerosis an autoimmune disease
 
Atherosclerosis, an autoimmune disease 2
Atherosclerosis, an autoimmune disease 2Atherosclerosis, an autoimmune disease 2
Atherosclerosis, an autoimmune disease 2
 
kayleighreport2014
kayleighreport2014kayleighreport2014
kayleighreport2014
 
Aeha multipeptide and passive
Aeha multipeptide and passiveAeha multipeptide and passive
Aeha multipeptide and passive
 
Atherosclerosis an autoimmune disease
Atherosclerosis  an autoimmune diseaseAtherosclerosis  an autoimmune disease
Atherosclerosis an autoimmune disease
 
501 autoimmune disease
501 autoimmune disease501 autoimmune disease
501 autoimmune disease
 
06 rencontres biomédicale LIR A Tedgui
06 rencontres biomédicale LIR A Tedgui06 rencontres biomédicale LIR A Tedgui
06 rencontres biomédicale LIR A Tedgui
 
074 influenza infection effects
074 influenza infection effects074 influenza infection effects
074 influenza infection effects
 
Immunità acquisita nelle IBD
Immunità acquisita nelle IBDImmunità acquisita nelle IBD
Immunità acquisita nelle IBD
 
Drnaghavi
DrnaghaviDrnaghavi
Drnaghavi
 

Viewers also liked

The prev of inf cells in nonrupt a. plaque pasterkamp- part 2
The prev of inf cells in nonrupt a. plaque  pasterkamp- part 2The prev of inf cells in nonrupt a. plaque  pasterkamp- part 2
The prev of inf cells in nonrupt a. plaque pasterkamp- part 2
Society for Heart Attack Prevention and Eradication
 
Flujo de conserva natural
Flujo de conserva naturalFlujo de conserva natural
Flujo de conserva natural
Carlos Alberto Ramirez
 
Kbj stock verification
Kbj stock verificationKbj stock verification
Kbj stock verificationpratapbarik
 
Educación virtual Valentín castro
Educación virtual Valentín castro Educación virtual Valentín castro
Educación virtual Valentín castro
valecastro27
 
DEBER 2
DEBER 2DEBER 2
DEBER 2
edugarcia_99
 
LIGHTING by Keyani
LIGHTING by KeyaniLIGHTING by Keyani
LIGHTING by Keyani
shahzad raki
 
Leyendo y escribiendo con tics aprendo y me
Leyendo y escribiendo con tics aprendo y meLeyendo y escribiendo con tics aprendo y me
Leyendo y escribiendo con tics aprendo y me
carmenxitacruz
 
Crear Cuenta Gmail
Crear Cuenta GmailCrear Cuenta Gmail
Crear Cuenta Gmail
guest550e3e
 
Complementary Professions? Occupational Therapy and Occupational Health in t...
Complementary Professions?  Occupational Therapy and Occupational Health in t...Complementary Professions?  Occupational Therapy and Occupational Health in t...
Complementary Professions? Occupational Therapy and Occupational Health in t...
Royal College of Occupational Therapists
 
Product Testimonials
Product TestimonialsProduct Testimonials
Product Testimonials
slevin0711
 
DiseñO De Reactores
DiseñO De ReactoresDiseñO De Reactores
DiseñO De Reactores
guest5b8055
 
Support Dementia: using wearable assistive technology and analysing real-time...
Support Dementia: using wearable assistive technology and analysing real-time...Support Dementia: using wearable assistive technology and analysing real-time...
Support Dementia: using wearable assistive technology and analysing real-time...
Interactive Technologies and Games: Education, Health and Disability
 
Royale Business Club
Royale Business ClubRoyale Business Club
Royale Business Club
Le Medra Singapore
 
Prognostic Indicators and Outcome Measures_4-5
Prognostic Indicators and Outcome Measures_4-5Prognostic Indicators and Outcome Measures_4-5
Prognostic Indicators and Outcome Measures_4-5
Michelle Sheridan
 
Hybrid - Official Business Presentation
Hybrid - Official Business PresentationHybrid - Official Business Presentation
Hybrid - Official Business Presentation
Raymond Red
 
Cybercrime Awareness Campaign
Cybercrime Awareness CampaignCybercrime Awareness Campaign
Cybercrime Awareness Campaign
Jessica Anandajoo
 
Principles of use of plaster of paris
Principles of use of plaster of parisPrinciples of use of plaster of paris
Principles of use of plaster of paris
Asi-oqua Bassey
 
8 steps for excellent B2B CX (customer experience)
8 steps for excellent B2B CX (customer experience)8 steps for excellent B2B CX (customer experience)
8 steps for excellent B2B CX (customer experience)
B2B Marketing
 

Viewers also liked (19)

The prev of inf cells in nonrupt a. plaque pasterkamp- part 2
The prev of inf cells in nonrupt a. plaque  pasterkamp- part 2The prev of inf cells in nonrupt a. plaque  pasterkamp- part 2
The prev of inf cells in nonrupt a. plaque pasterkamp- part 2
 
BLS card
BLS cardBLS card
BLS card
 
Flujo de conserva natural
Flujo de conserva naturalFlujo de conserva natural
Flujo de conserva natural
 
Kbj stock verification
Kbj stock verificationKbj stock verification
Kbj stock verification
 
Educación virtual Valentín castro
Educación virtual Valentín castro Educación virtual Valentín castro
Educación virtual Valentín castro
 
DEBER 2
DEBER 2DEBER 2
DEBER 2
 
LIGHTING by Keyani
LIGHTING by KeyaniLIGHTING by Keyani
LIGHTING by Keyani
 
Leyendo y escribiendo con tics aprendo y me
Leyendo y escribiendo con tics aprendo y meLeyendo y escribiendo con tics aprendo y me
Leyendo y escribiendo con tics aprendo y me
 
Crear Cuenta Gmail
Crear Cuenta GmailCrear Cuenta Gmail
Crear Cuenta Gmail
 
Complementary Professions? Occupational Therapy and Occupational Health in t...
Complementary Professions?  Occupational Therapy and Occupational Health in t...Complementary Professions?  Occupational Therapy and Occupational Health in t...
Complementary Professions? Occupational Therapy and Occupational Health in t...
 
Product Testimonials
Product TestimonialsProduct Testimonials
Product Testimonials
 
DiseñO De Reactores
DiseñO De ReactoresDiseñO De Reactores
DiseñO De Reactores
 
Support Dementia: using wearable assistive technology and analysing real-time...
Support Dementia: using wearable assistive technology and analysing real-time...Support Dementia: using wearable assistive technology and analysing real-time...
Support Dementia: using wearable assistive technology and analysing real-time...
 
Royale Business Club
Royale Business ClubRoyale Business Club
Royale Business Club
 
Prognostic Indicators and Outcome Measures_4-5
Prognostic Indicators and Outcome Measures_4-5Prognostic Indicators and Outcome Measures_4-5
Prognostic Indicators and Outcome Measures_4-5
 
Hybrid - Official Business Presentation
Hybrid - Official Business PresentationHybrid - Official Business Presentation
Hybrid - Official Business Presentation
 
Cybercrime Awareness Campaign
Cybercrime Awareness CampaignCybercrime Awareness Campaign
Cybercrime Awareness Campaign
 
Principles of use of plaster of paris
Principles of use of plaster of parisPrinciples of use of plaster of paris
Principles of use of plaster of paris
 
8 steps for excellent B2B CX (customer experience)
8 steps for excellent B2B CX (customer experience)8 steps for excellent B2B CX (customer experience)
8 steps for excellent B2B CX (customer experience)
 

Similar to Towards immune modulation vp

178 vaccination against atherosclerosis
178 vaccination against atherosclerosis178 vaccination against atherosclerosis
178 vaccination against atherosclerosis
SHAPE Society
 
189 hsp 65
189 hsp 65189 hsp 65
189 hsp 65
SHAPE Society
 
Mark A. Atkinson
Mark A. AtkinsonMark A. Atkinson
Mark A. Atkinson
JDRF New England Chapter
 
Immunotherapy Web Presentation
Immunotherapy   Web PresentationImmunotherapy   Web Presentation
Immunotherapy Web Presentation
anthonymaida
 
Drugs acting on the immune system
Drugs acting on the immune systemDrugs acting on the immune system
Drugs acting on the immune system
ShaikhSaniya2
 
inflammation in mice.pdf
inflammation in mice.pdfinflammation in mice.pdf
inflammation in mice.pdf
SyedZada33
 
Immunology 1, 2, 3
Immunology 1, 2, 3Immunology 1, 2, 3
Immunology 1, 2, 3
Ahmed Elshebiny
 
State of Lupus Treatment: New Therapeutics
State of Lupus Treatment: New TherapeuticsState of Lupus Treatment: New Therapeutics
State of Lupus Treatment: New Therapeutics
LupusNY
 
07. immunology
07. immunology07. immunology
07. immunology
Bassant Alaa
 
238570.pptx
238570.pptx238570.pptx
238570.pptx
Ashiqur Rahman
 
Understanding immunology for internists 1
Understanding immunology for internists   1Understanding immunology for internists   1
Understanding immunology for internists 1
Ahmed Elshebiny
 
Ferretti et al., BBI 2016
Ferretti et al., BBI 2016Ferretti et al., BBI 2016
Ferretti et al., BBI 2016
Maria Teresa Ferretti
 
Common variable immunodeficiency 2017
Common variable immunodeficiency 2017Common variable immunodeficiency 2017
Harats
HaratsHarats
242 lipid lowering
242 lipid lowering242 lipid lowering
242 lipid lowering
242 lipid lowering242 lipid lowering
242 lipid lowering
SHAPE Society
 
Esv2n37 b
Esv2n37 bEsv2n37 b
Immunosenescence
ImmunosenescenceImmunosenescence
Immunosenescence
Godwin J
 
243 b cell
243 b cell243 b cell
243 b cell
SHAPE Society
 
Cellular Adhesion in Inflammation
Cellular Adhesion in InflammationCellular Adhesion in Inflammation

Similar to Towards immune modulation vp (20)

178 vaccination against atherosclerosis
178 vaccination against atherosclerosis178 vaccination against atherosclerosis
178 vaccination against atherosclerosis
 
189 hsp 65
189 hsp 65189 hsp 65
189 hsp 65
 
Mark A. Atkinson
Mark A. AtkinsonMark A. Atkinson
Mark A. Atkinson
 
Immunotherapy Web Presentation
Immunotherapy   Web PresentationImmunotherapy   Web Presentation
Immunotherapy Web Presentation
 
Drugs acting on the immune system
Drugs acting on the immune systemDrugs acting on the immune system
Drugs acting on the immune system
 
inflammation in mice.pdf
inflammation in mice.pdfinflammation in mice.pdf
inflammation in mice.pdf
 
Immunology 1, 2, 3
Immunology 1, 2, 3Immunology 1, 2, 3
Immunology 1, 2, 3
 
State of Lupus Treatment: New Therapeutics
State of Lupus Treatment: New TherapeuticsState of Lupus Treatment: New Therapeutics
State of Lupus Treatment: New Therapeutics
 
07. immunology
07. immunology07. immunology
07. immunology
 
238570.pptx
238570.pptx238570.pptx
238570.pptx
 
Understanding immunology for internists 1
Understanding immunology for internists   1Understanding immunology for internists   1
Understanding immunology for internists 1
 
Ferretti et al., BBI 2016
Ferretti et al., BBI 2016Ferretti et al., BBI 2016
Ferretti et al., BBI 2016
 
Common variable immunodeficiency 2017
Common variable immunodeficiency 2017Common variable immunodeficiency 2017
Common variable immunodeficiency 2017
 
Harats
HaratsHarats
Harats
 
242 lipid lowering
242 lipid lowering242 lipid lowering
242 lipid lowering
 
242 lipid lowering
242 lipid lowering242 lipid lowering
242 lipid lowering
 
Esv2n37 b
Esv2n37 bEsv2n37 b
Esv2n37 b
 
Immunosenescence
ImmunosenescenceImmunosenescence
Immunosenescence
 
243 b cell
243 b cell243 b cell
243 b cell
 
Cellular Adhesion in Inflammation
Cellular Adhesion in InflammationCellular Adhesion in Inflammation
Cellular Adhesion in Inflammation
 

More from Society for Heart Attack Prevention and Eradication

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
Society for Heart Attack Prevention and Eradication
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
Society for Heart Attack Prevention and Eradication
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
Society for Heart Attack Prevention and Eradication
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
Society for Heart Attack Prevention and Eradication
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
Society for Heart Attack Prevention and Eradication
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
Society for Heart Attack Prevention and Eradication
 
Vp watch2002
Vp watch2002Vp watch2002
Vp symposium31602
Vp symposium31602Vp symposium31602
Vpschoenhagen
VpschoenhagenVpschoenhagen

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 

Recently uploaded

The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
Hiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital Powai News [Read Now].pdfHiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital Powai News [Read Now].pdf
Dr. Sujit Chatterjee CEO Hiranandani Hospital
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
KafrELShiekh University
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 

Recently uploaded (20)

The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
Hiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital Powai News [Read Now].pdfHiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital Powai News [Read Now].pdf
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 

Towards immune modulation vp

  • 1. Towards Immune Modulation against Vulnerable Plaque Göran K Hansson Center for Molecular Medicine Karolinska Institutet Stockholm, Sweden Vulnerable Plaque Symposium Chicago, IL, November 2002
  • 2. Hansson, Libby, Schönbeck & Yan, Circ Res 2002
  • 3. Potential targets for immunomodulation of atherosclerosis • Specific antigens – oxLDL, HSP65, β2GpI, microbial • C pneum, CMV, others • Co-stimulatory molecules – CD40/CD40L, CD28/B7 • Cytokines – IFNγ, TNFα (aggravating) – IL-10, TGFβ (protective) • Vaccines • Recombinant proteins • Antibodies • Cells • Small molecule drugs
  • 4. Atherosclerosis in the absence of adaptive immunity? (G K Hansson & J Nilsson, in: Crawford & DiMarco, Cardiology)
  • 5. CD4+ T cells aggravate atherosclerosis in immunodeficient apoExSCID mice * ApoE- SCID ApoE- T and B cells No CD4+ T Yes transfer Aortic lesion size Zhou, Nicoletti, Elhage & Hansson Circ 102:2919 2000 ApoE- SCID
  • 6. Immunosuppression to reduce CD4+ T cell activity? • General immunosuppression is likely to reduce atherosclerosis – Some support from animal studies • But substantial side effects – Infections – Direct vascular effects of drugs • Therefore, general immunosuppression is unlikely to be used to treat atherosclerosis or even vulnerable plaque
  • 7. Complexity of immune regulatory networks • Counterbalancing cell subsets • Idiotypic antibody networks • Regulatory cytokines
  • 8. The Th1/Th2 Paradigm Th IL-12 MHC Peptide TCRTCR IFN-γ IL-18 Th1 IFN-γ MΦ IFN-γ B Ab DTH InflammationAPC APC Th IL-4 Th2Th2 B IL-3, 5 IL-4 IL-10 IL-13 - IL-4, 10, 13 Antibodies Allergy
  • 9. Hypothesis: Th1/Th2 balance controls atherosclerosis – Th1 cells dominate in lesions and are proatherogenic • CD4+ Th1 cells (Hansson 89; Uyemura 96; Frostegård 99) • Interferon-γ, TNF-α; IL-12, IL-18 (Zhou 00; Mallat 01; Daugherty 01) –Th2 cytokines that inhibit Th1 may be antiatherogenic? – IL-10-/- B6 mice develop larger fatty streaks – IL-10 administration reduces disease » Mallat et al; Pinderski et al. 99
  • 10. Increased atherosclerosis in IL-10 deficient apoE-/- mice IL10-/- E-/- IL10+/+ E-/- Caligiuri, Hansson, Rudling, Michel, Nicoletti 2002 * 100 50 Lesion size (x 103 µm2) in 16 wks old mice
  • 11. Antiatherosclerotic cytokines - useful for therapy? • Powerful, direct approach • Recombinant cytokines available • But these cytokines are usually immunosuppressive / antiinflammatory, therefore – Increased sensitivity to infections – Cytokine-specific side effects • E.g. TGFβ – fibrosis • Therefore, these cytokines might be useful in acute coronary syndromes, • although not in chronic atherosclerosis
  • 12. Inflammation Repair Innate immunity / TLRs Adaptive Th1 immunity IFN-γ TNF-α, IL-1 Inhibitory cytokines Cells? IL-10 TGF-β Ab? Accelerated athero Plaque activation Reduced athero Stable plaque Silent disease Immune regulation of plaque activity
  • 13. B cells of atherosclerotic mice carry atheroprotective immunity 0 50 100 150 200 250 Sham Sx Sx Sx Transfer - - T B * * ‡ ‡ Lesionsize Caligiuri et al, JCI 109:745, 2002 ApoE mice Sx, trf 6 wk age Analysis 18 wk
  • 14. Atheroprotective immunity • Carried by spleen B cells • Reduces lesion size and stage • Reduces CD4+ T cell infiltration in lesions • Correlates with anti-oxLDL antibodies • Protective effect of antibodies? – Clearance of oxLDL?
  • 15. Protective immunity against atherosclerosis • Can we induce it by immunization? • A vaccination strategy against atherosclerosis?
  • 16. Protective immunization 1. Oxidized LDL Parenteral immunization (sc) Model: Mutant rabbits, mice Antigen: OxLDL, MDA-LDL Freund´s adjuvant Repeated inj 3 wk intervals Significant protection after 3 months! Palinski PNAS 95; Ameli ATVB 96; George Athero 99; Zhou ATVB 00
  • 17. MDA-LDL ”vaccination” reduces atherosclerosis Immunogen (PBS) Plaque MDA-LDL extract ApoE-/- mice Immun wk 6 / FCA Boost wk 8,10,12,14 Analysis wk 18 Zhou et al, ATVB 2000
  • 18. Protective immunization 2. Heat shock protein 65/60 • HSP60 released upon cell injury and in atherosclerosis – Wick, Xu et al. 1992 • HSP65/60 X-reacts man-microbe • Mucosal administration of HSP65 – Nasal, oral • Reduced lesions in LDLR mice – Maron, Libby, Weiner, Circ 2002 – Harats, Shoenfeld, George, JACC 2002
  • 19. Inflammation Repair Innate immunity / TLRs Adaptive Th1 immunity IFN-γ TNF-α, IL-1 Inhibitory cytokines Protective B cells IL-10 TGF-β Ab? MΦ activation Endothelial activation Radicals Proteinases Prothrombotic state Antiinflammation Fibrosis SMC proliferation Antibody clearance Immune regulation of plaque activity Vaccine
  • 20. Small molecule drugs that modulate athero-immunity • Pentoxifyllin – Inhibits Th1 immune responses – Inhibits atherosclerosis in mice • Laurat et al Circ 2001 • Statins – Inhibit Th1 responses! • Kwak Nat Med 2000; Youssef Nature 2002 – Inhibit atherosclerosis in mice and men
  • 21. Statins inhibit Th1 immunity • Downregulate interferon-γ induced HLA-II transcription in macrophages – Kwak, Mach et al, Nature Med 2000 • Inhibit Th1 signalling • Increase Th2 cytokines • Inhibit autoimmune encephalomyelitis – Youssef, Steinman et al, Nature 2002
  • 22. Inflammation Repair Innate immunity / TLRs Adaptive Th1 immunity IFN-γ TNF-α, IL-1 Inhibitory cytokines Protective B cells IL-10 TGF-β Ab MΦ activation Endothelial activation Radicals Proteinases Prothrombotic state Antiinflammation Fibrosis SMC proliferation Antibody clearance Immune modulation of vulnerable plaque Vaccines Drugs